SCHEMBL5678859

SCHEMBL5678859

CC1CC(=O)NN=C1c1ccc(N/N=C/c2ccc(O)c([N+](=O)[O-])c2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 9/20 0.52
▸ GALR3 O60755 3/20 0.52
▸ THRB P10828 2/20 0.52
▸ PDE3B Q13370 6/20 0.52
▸ PDE3A Q14432 6/20 0.52
▸ TNNC1 P63316 1/20 0.52
▸ ALDH1A1 P00352 8/20 0.51
▸ GAA P10253 2/20 0.51
▸ SMN1; SMN2 Q16637 4/20 0.51
▸ KDM4E B2RXH2 3/20 0.50
▸ PKM P14618 1/20 0.49
▸ LMNA P02545 3/20 0.48
▸ MAPK1 P28482 3/20 0.48
▸ SLFN12 Q8IYM2 1/20 0.48
▸ BLM P54132 3/20 0.47
▸ NPSR1 Q6W5P4 3/20 0.47
▸ MEN1 O00255 3/20 0.47
▸ POLB P06746 3/20 0.47
▸ RECQL P46063 3/20 0.47
▸ KMT2A Q03164 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5678864 1.00 MAPT (0.52) MAPTGALR3THRBPDE3BPDE3A
SCHEMBL27494992 0.88 MAPT (0.52) MAPTGALR3THRBPDE3BPDE3A
SCHEMBL5680473 0.86 PDE3B (0.54) MAPTGALR3THRBPDE3BPDE3A
SCHEMBL5680478 0.86 PDE3B (0.54) MAPTGALR3THRBPDE3BPDE3A
SCHEMBL5677353 0.85 MAPT (0.52) MAPTGALR3THRBPDE3BPDE3A
SCHEMBL5677347 0.85 MAPT (0.52) MAPTGALR3THRBPDE3BPDE3A
SCHEMBL5679128 0.84 PDE3B (0.52) MAPTGALR3THRBPDE3BPDE3A
SCHEMBL5679134 0.84 PDE3B (0.52) MAPTGALR3THRBPDE3BPDE3A
SCHEMBL5681543 0.83 PDE3B (0.60) MAPTPDE3BPDE3ATNNC1ALDH1A1
SCHEMBL5681538 0.83 PDE3B (0.60) MAPTPDE3BPDE3ATNNC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1265871-B1 PYRIDAZINYL PHENYL HYDRAZONES USEFUL AGAINST CONGESTIVE HEART FAILURE ORION CORP (FI) 2006-02-08 — — EP disclosed
US-6699868-B2 INCREASE THE CALCIUM SENSITIVITY OF CONTRACTILE PROTEINS OF THE CARDIAC MUSCLE ORION CORPORATION (FI) 2004-03-02 — — US disclosed
US-20030158200-A1 Pyridazinyl phenyl hydrazones useful against congestive heart failure ORION CORPORATION (FI) 2003-08-21 — — US disclosed
EP-1265871-A1 PYRIDAZINYL PHENYL HYDRAZONES USEFUL AGAINST CONGESTIVE HEART FAILURE ORION CORPORATION (FI) 2002-12-18 — — EP disclosed
WO-2001068611-A1 PYRIDAZINYL PHENYL HYDRAZONES USEFUL AGAINST CONGESTIVE HEART FAILURE ORION CORPORATION (FI) 2001-09-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158200-A1 Pyridazinyl phenyl hydrazones useful against congestive heart failure FABP3, TNNI3, TNNT2 MAPT 4871/4885GALR3 2025/4885THRB 1658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback